Arévalo MFG, Badia FJJ, Arciniega AA

Language: Spanish
References: 26
Page: 108-110
PDF size: 192.29 Kb.

Text Extraction

No abstract.

REFERENCES

1. Khan MA. Ankylosing spondylitis: clinical aspects. In: Calin A, Taurog JD, editors. The spondyloarthritides. Oxford: Oxford University Press; 1998. pp. 27-40.

2. Malinowski KP, Kaealec P. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15 (2): 285-300.

3. Toussirot É. Diagnosis and management of late-onset spondyloarthritis: implications of treat-to-target recommendations. Drugs Aging. 2015; 32 (7): 515-524.

4. Burgos-Vargas R, Naranjo A, Castillo J, Katona G. Ankylosing spondylitis in the Mexican mestizo: patterns of disease according to age at onset. J Rheumatol. 1989; 16: 186-191.

5. Olivieri I, Salvarini C, Cantini F, Ciancio G, Padula A. Ankylosing spondylitis and undifferentiated spondyloarthropaties: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol. 2001; 13: 280-284.

6. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R et al. The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68 Suppl 2: ii1-44.

7. Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH. The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum. 2012; 64 (5): 1407-1411.

8. Baron M, Zendel I. HLA-B27 testing in ankylosing spondylitis: an analysis of the pretesting assumptions. J Rheumatol. 1989; 16 (5): 631-634; discussion 634-636.

9. Khan MA, Skosey JL. Ankylosing spondylitis and related spondyloarthropathies. In: Samter M, editor. Immunological diseases. Boston: Little, Brown; 1988. pp. 1509-1538.

10. Hidding A, van der Linden S, Boers M, Gielen X, de Witte L, Kester A et al. Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res. 1993; 6 (3): 117-125.

11. Dougados M, Béhier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001; 44 (1): 180-185.

12. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995; 38 (5): 618-627.

13. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006; 33 (4): 722-731.

14. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis. 2014; 73 (1): 243-246.

15. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis. 2008; 67 (3): 340-345.

16. Cantini F, Niccoli L, Benucci M, Chindamo D, Nannini C, Olivieri I et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum. 2006; 55 (5): 812-816.

17. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005; 52 (8): 2447-2451.

18. Jois RN, Gaffney K, Keat A. Anti-tumour necrosis factor therapy for ankylosing spondylitis —unresolved issues. Rheumatology (Oxford). 2007; 46 (6): 899-901.

19. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003; 48 (11): 3230-3236.

20. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54 (7): 2136-2146.

21. Reveille JD. Epidemiology of spondyloarthritis in North America. Am J Med Sci. 2011; 341 (4): 284-286.

22. Andreu JL, Otón T, Sanz J. Terapia anti-TNF alfa en espondilitis anquilosante: control sintomático y modificación del dańo estructural. Reumatol Clin. 2011; 7: 51-55.

23. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther. 2009; 11 (2): 221.

24. Busquets N, Carmona L, Surís J. Revisión sistemática: eficacia y seguridad del tratamiento anti-TNF en pacientes ancianos. Reumatol Clin. 2011; 7: 104-112.

25. Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology. 2005; 44: 695-696.

26. Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007; 24: 239-254.